Toc is a monoclonal antibody targeting IL-6 receptors that has shown effectiveness in patients with TAO unresponsive to steroids,7 its therapeutic efficacy is often limited by challenges in targeted delivery. This evidence concerns the gene RHBDF2 and thromboangiitis obliterans.